Treatment of malignant hypercalcaemia with clodronate

R. C. Percival; A. D. Paterson; A. J.P. Yates; D. J. Beard; D. L. Douglas; F. E. Neal; R. G.G. Russell; J. A. Kanis

Journal Article

Treatment of malignant hypercalcaemia with clodronate

British Journal of Cancer (1985) 51(5) 665-669

DOI: 10.1038/bjc.1985.100

44Citations

6Readers

Get full text

Abstract

We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8–3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppressed for the duration of treatment, but recurred promptly when treatment was stopped. Clodronate may be a useful measure for controlling hypercalcaemia and osteolysis in patients with carcinoma. © 1985, The Macmillan Press Ltd.

Cite

CITATION STYLE

APA

Percival, R. C., Paterson, A. D., Yates, A. J. P., Beard, D. J., Douglas, D. L., Neal, F. E., … Kanis, J. A. (1985). Treatment of malignant hypercalcaemia with clodronate. British Journal of Cancer, 51(5), 665–669. https://doi.org/10.1038/bjc.1985.100

Treatment of malignant hypercalcaemia with clodronate

Abstract

Cite

Register to see more suggestions